AN2 Therapeutics (ANTX) Other Non-Current Assets (2022 - 2025)
AN2 Therapeutics (ANTX) reported Other Non-Current Assets of $304000.0 for Q1 2025, down 70.85% year-over-year from $1.0 million in Q1 2024, and down 62.19% quarter-over-quarter from $804000.0 in Q4 2024.
AN2 Therapeutics (ANTX) Other Non-Current Assets (2022 - 2025) Analysis & Trends
AN2 Therapeutics (ANTX) has 4 years of Other Non-Current Assets data on file, last reported at $304000.0 in Q1 2025.
- Other Non-Current Assets for Q1 2025 came in at $304000.0, down 70.85% year-over-year; the trailing twelve-month figure through Mar 2025 was $304000.0 (down 70.85% YoY), and the FY2024 annual result was $804000.0, down 22.91% from the prior year.
- Other Non-Current Assets declined to $304000.0 in Q1 2025 per ANTX's latest filing, from $804000.0 in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $1.0 million in Q3 2023 and troughed at $304000.0 in Q1 2025.
- A 4-year average of $800000.0 and a median of $720000.0 in 2022 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2023 and 2025: Other Non-Current Assets jumped 44.86% in 2023, then slumped 70.85% in 2025.
- A 4-year view of Other Non-Current Assets shows it stood at $720000.0 in 2022, then jumped by 44.86% to $1.0 million in 2023, then decreased by 22.91% to $804000.0 in 2024, then plunged by 62.19% to $304000.0 in 2025.
- Business Quant data shows ANTX's Other Non-Current Assets at $304000.0 in Q1 2025, $804000.0 in Q4 2024, and $1.0 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 12.40 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | 60,000.00 |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 1.26 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | AN2 Therapeutics | 161.95 Mn | 161.95 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 304,000.00 |
| Dec 31, 2024 | 804,000.00 |
| Jun 30, 2024 | 1.04 Mn |
| Mar 31, 2024 | 1.04 Mn |
| Dec 31, 2023 | 1.04 Mn |
| Sep 30, 2023 | 1.04 Mn |
| Jun 30, 2023 | 720,000.00 |
| Mar 31, 2023 | 720,000.00 |
| Dec 31, 2022 | 720,000.00 |
| Sep 30, 2022 | 720,000.00 |
| Jun 30, 2022 | 720,000.00 |
| Mar 31, 2022 | 720,000.00 |